康艾注射液对TACE联合MWA治疗后肝癌患者疗效影响的研究

目的 探究康艾注射液对肝动脉插管化疗栓塞(TACE)联合微波消融(MWA)治疗后肝癌患者疗效的影响.方法 对92例肝癌患者的病历资料进行回顾性分析.根据治疗方法不同将患者分为治疗组及对照组,每组各46例.对照组患者接受TACE联合MWA治疗方案进行治疗,治疗组患者在对照组治疗方案的基础上加用康艾注射液进行治疗.对两组患者治疗前后甲胎蛋白(AFP)水平、丙氨酸转移酶(ALT)水平、凝血功能、治疗总有效率以及不良反应发生情况进行比较.结果 治疗前,两组患者的AFP水平、ALT水平及凝血功能比较,差异均无统计学意义(P﹥0.05);治疗后,治疗组患者的ALT及AFP水平均低于对照组(P﹤0.05);治疗组患者的治疗总有效率高于对照组(P﹤0.05);治疗过程中,治疗组患者的白细胞下降、血红蛋白下降发生率均低于对照组(P﹤0.05).结论 康艾注射液可增强TACE联合MWA方案对肝癌的治疗总有效率,降低治疗用药对肝功能的不良影响及不良反应发生情况.

The effect of Kang'ai injection in patients with hepatocellular carcinoma treated with TACE combined with MWA

Objective To explore the effect of Kang'ai injection in patients with hepatocellular carcinoma treated with trancatheter arterial chemoembolization (TACE) combined with microwave ablation (MWA). Method 92 cases of patients with hepatocellular carcinoma treated by TACE combined with MWA were retrospectively analyzed, patients in study group (n=46) were administered with TACE + WMA+ Kang'ai injection, while those in control group (n=46) were given TACE + WMA only, the levels of AFP, ALT, coagulation function, overall response rate and adverse reac-tions were compared between the two groups before and after treatment. Result There was no significant difference in AFP, ALT and coagulation function between the two groups before treatment (P>0.05);while after treatment, the levels of ALT and AFP in the study group were lower than those in the control group (P<0.05);the overall response rate was higher in the study group than control group (P<0.05);during the therapy, the study group had lower incidence of leuko-penia and decreased hemoglobin compared with control group (P<0.05). Conclusion Kang'ai injection enhances the overall response rate for patients with hepatocellular carcinoma receiving TACE combined with MWA, thus reduces the damage to liver function and adverse reactions induced by the medications.